AbbVie Inc. (ABBV)
107.00 +0.30 (0.28%)
After hours: 5:44PM EST
| Previous close | 105.65 |
| Open | 106.01 |
| Bid | 106.92 x 1100 |
| Ask | 106.75 x 900 |
| Day's range | 104.07 - 106.99 |
| 52-week range | 62.55 - 113.41 |
| Volume | 7,007,488 |
| Avg. volume | 7,222,100 |
| Market cap | 188.419B |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | 39.23 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 5.20 (4.87%) |
| Ex-dividend date | 14 Apr 2021 |
| 1y target est | N/A |
- PR Newswire
Allergan, an AbbVie Company, Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia
Allergan, an AbbVie (NYSE: ABBV) company, today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the NDA by the end of 2021.
- PR Newswire
HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. In clinical trials, HUMIRA induced clinical remission at Week 8 and maintained remission at Week 52 in patients who responded at Week 8.1,2
- PR Newswire
New REFRESH® DIGITAL Lubricant Eye Drops Tackle Eye Dryness Due to Everyday Screen Use
From scrolling through social media feeds, to video conferences for work and school, to relaxing with television and video games, Americans are spending approximately 13 hours a day on some type of digital device.1 As the reliance on screens to connect digitally for both professional and personal use continues to rise, more than half of adults suffer from digital eye strain,2 which often includes dry, irritated eyes.
